Clinical trial
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial…
NCT00005051 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00005051 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer |
| Official title | Phase II Study of First-Line Therapy of Ovarian Cancer With Sequential Regimens: Cisplatin-Prolonged Oral Topotecan (C-PORT) Followed by Paclitaxel/Carboplatin (PC) |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, cisplatin, paclitaxel, topotecan hydrochloride |
| Start date | Aug 1, 1999 |
| Primary completion | Mar 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 9, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: